TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7942937
Drug: Intermittent very-low-calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent very-low-calorie diet (VLCD) of 400 to 500 kcal per day for 12 weeks, alternating with a balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Study: 7942937
Drug: Balanced low-calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Study: 2897388
Drug: loratadine, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine, 40 mg once daily
Study: 2897388
Drug: terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine, 60 mg twice daily
Study: 30100375
Drug: Mogamulizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (1.0 mg/kg intravenously weekly for the first 28-day cycle, then on days 1 and 15 of subsequent cycles)
Study: 30100375
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg daily)
Study: 24815533
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg QD
Study: 24815533
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg QD
Study: 22205424
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy for flight phobia (specific dosage and duration not mentioned)
Study: 22205424
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy for flight phobia
Study: 18541590
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation, mean daily dose of 86 microg (3440 IU) adjusted every 2 months based on serum 25(OH)D concentration.
Study: 18541590
Drug: Computer simulations
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Computer simulations for optimal daily dose of vitamin D(3).
Study: 18541590
Drug: Projected dose-response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Projected dose-response curves for different baseline 25(OH)D concentrations.
Study: 11054193
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled flunisolide 2 mg/d
Study: 9089000
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (tablet Krewel)
Study: 9089000
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation 1 (suspension Krewel)
Study: 9089000
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation 2 (tablet Muskel Trancopal)
Study: 8447567
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium 50 mg on the evening before operation and 25 mg on the morning of the operation
Study: 8447567
Drug: Flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1 mg p.o. on the evening before the operation
Study: 3082613
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone treatment (100 micrograms thyroxin)
Study: 29669934
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH)
Study: 8299238
Drug: Soy diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy diet plus 5 g/day of fish oil (SD + FO)
Study: 2834502
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Kabi 2165)
Study: 2834502
Drug: Non-fractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractionated heparin
Study: 19096768
Drug: Letrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5 years' monotherapy)
Study: 19096768
Drug: Tamoxifen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (5 years' monotherapy)
Study: 19096768
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (2 years tamoxifen followed by 3 years letrozole)
Study: 19096768
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (2 years letrozole followed by 3 years tamoxifen)
Study: 16870078
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg tablets
Study: 10229430
Drug: Active nonsteroidal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nonsteroidal antiinflammatory drug (NSAID)
Study: 2010061
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (500 mg/day)
Study: 7099731
Drug: Methylphenidate (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (dosage adjusted based on nervous system classification)
Study: 31936720
Drug: Walnut consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut consumption (Juglans regia L.) for 4 weeks
Study: 22183214
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg synthetic conjugated estrogens-B
Study: 22183214
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg synthetic conjugated estrogens-B
Study: 20815158
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers (Propranolol, Atenolol, Pindolol)
Study: 9453014
Drug: Beta-blocker (BBL)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker (BBL)
Study: 9453014
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitor (CEI)
Study: 9453014
Drug: Alpha-blocker (ABL)
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker (ABL)
Study: 31619335
Drug: Medetomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (bolus dose, 5 μg kg‐1; CRI, 3.5 μg kg‐1 hour‐1)
Study: 31619335
Drug: Detomidine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (bolus dose, 10 μg kg‐1; CRI, 6 μg kg‐1 hour‐1)
Study: 31554370
Drug: Piperacillin/Tazobactam (PIP/TZO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/Tazobactam (PIP/TZO) 320 mg/kg/day divided every 8 hours
Study: 31554370
Drug: Ceftazidime 100
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 100 mg/kg/day divided every 8 hours plus Amikacin 15 mg/kg/day once daily
Study: 27522630
Drug: CA125-guided therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CA125-guided therapy (CA125 strategy)
Study: 20861586
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg NWP06 (extended-release methylphenidate)
Study: 20861586
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg immediate-release methylphenidate (IR MPH)
Study: 20861586
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg NWP06
Study: 16422874
Drug: On-demand tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-demand tadalafil (20 mg)
Study: 16422874
Drug: Daily tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily tadalafil (10 mg)
Study: 12660257
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (two different regimens)
Study: 10618463
Drug: Chronic imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic imipramine treatment
Study: 1862965
Drug: Multicomponent endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent endotracheal anesthesia with controlled lung ventilation and postoperative intramuscular analgesia with non-narcotic and narcotic analgesics (Group I)
Study: 1862965
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with 2.5% trimecaine solution combined with adrenaline and small morphine doses at the upper thoracic segment level, with postoperative analgesia for 18 hours (Group II)
Study: 6412263
Drug: Bupropion (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (100, 200, 400 mg)
Study: 6412263
Drug: Dextroamphetamine (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (15, 30 mg)
Study: 30720444
Drug: 0.9% cadexomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% cadexomer iodine ointment plus standard care
Study: 18163919
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (LDD) 20 mg twice a day for 10 weeks
Study: 9649964
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (10, 30, 56, and 100 mg)
Study: 9649964
Drug: LY297802 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY297802 (0.1, 0.3, 0.56, and 1 mg)
Study: 7675376
Drug: Intracervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical PGE2 gel 0.5 mg administered at 6-hour intervals
Study: 2044014
Drug: Isosorbide-5-mononitrate 60
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate 60 mg once daily
Study: 2044014
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 30 mg qid
Study: 28474780
Drug: Abaloparatide-SC (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-SC (80 mcg daily subcutaneous injections for 18 months)
Study: 24576893
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 50% glucose only
Study: 24576893
Drug: 10 units
Normalized name: Omnipod GO 10 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units of insulin with 100 ml of 50% glucose (50 g)
Study: 17523386
Drug: Allergovit 6-grass
Normalized name: Buffalo grass
DrugBank: Anthoxanthum odoratum (DB14163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergovit 6-grass pollen preparation
Study: 9849475
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP) every 28 days for six courses
Study: 9849475
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 every 28 days for six courses
Study: 9849475
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CP)
Study: 12860938
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2
Study: 9849475
Drug: Platinum second-line
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum second-line therapy
Study: 8300993
Drug: Training with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training with a combination of food models and life-sized food photographs (experimental group, n = 18)
Study: 2230213
Drug: Topical all‐trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical all‐trans retinoic acid (0.05%) applied to the forearms for 6 months
Study: 2230213
Drug: Topical all‐trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical all‐trans retinoic acid (0.05%)
Study: 24001533
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg ranibizumab
Study: 21896561
Drug: Moxifloxacin iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin iv 400 mg once daily followed by oral 400 mg once daily
Study: 21896561
Drug: Piperacillin/tazobactam (TZP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (TZP) iv 4.0/0.5 g thrice daily followed by oral amoxicillin/clavulanate (AMC) 875/125 mg twice daily
Study: 21896561
Drug: Moxifloxacin iv/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin iv/oral
Study: 21896561
Drug: Piperacillin/tazobactam (TZP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (TZP) iv followed by oral amoxicillin/clavulanate (AMC)
Study: 15590951
Drug: Secondary surgical
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary surgical cytoreduction plus chemotherapy
Study: 9587124
Drug: Early adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early adjuvant radiation therapy (RT)
Study: 9587124
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (RT)
Study: 806293
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs combined (disodium cromoglycate and betamethasone 17 valerate)
Study: 31268555
Drug: Staccato alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staccato alprazolam 0.5 mg
Study: 24079396
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) treatment
Study: 16160572
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel applied
Study: 12834649
Drug: Cognitive-behavioral treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatments (CBT)
Study: 10825372
Drug: Mifepristone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone administration
Study: 1996621
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (10 mg/h) after pretreatment with dexamethasone (4 mg/day) for 4 or 6 days
Study: 1996621
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg/day) for 4 or 6 days
Study: 1996621
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (200 mg, at 0800 and 1700 h before experimental nights)
Study: 6324934
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/m2 daily for the entire treatment duration.
Study: 6324934
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of Tamoxifen (TAM) 20 mg/m2 daily for 15 days followed by Medroxyprogesterone acetate 350 mg/m2 daily for the next 15 days.
Study: 6324934
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of Tamoxifen (TAM) and Medroxyprogesterone acetate.
Study: 30840307
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg ketamine (Group K1)
Study: 30840307
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg ketamine (Group K1.5)
Study: 30840307
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ketamine (Group K2)
Study: 25304641
Drug: Sofosbuvir and
Normalized name: sofosbuvir and ledipasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and ribavirin combination therapy
Study: 22997785
Drug: Acupoint heat-sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint heat-sensitive moxibustion, 50 treatments over 3 months, 30 to 90 minutes each treatment.
Study: 22997785
Drug: Seretide inhaler,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide inhaler, one inhalation twice per day for 3 months.
Study: 17854448
Drug: Exercise-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based treatment designed to accelerate cerebellar development
Study: 12539003
Drug: Aprotinin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (both doses)
Study: 1852793
Drug: Fluoxetine (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40-80 mg/d)
Study: 1852793
Drug: Maprotiline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (50-150 mg/d)
Study: 31858234
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy (No HT)
Study: 30453379
Drug: 19 G
Normalized name: Sharps Collector 19 Gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 G Flex needle
Study: 27089361
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (G)
Study: 26390724
Drug: Dexamethasone (DEXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEXA) 6 mg/m2
Study: 26390724
Drug: Methylprednisolone (MePRED)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MePRED) 60 mg/m2
Study: 24100259
Drug: Aminophylline administration
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline administration
Study: 24628736
Drug: Vardenafil ODT
Normalized name: Vardenafil Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil ODT 10 mg
Study: 19214890
Drug: Lactulose/mannitol (L/M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose/mannitol (L/M) ratio
Study: 19214890
Drug: Saccharose excretion
Normalized name: Saccharose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saccharose excretion
Study: 19214890
Drug: L/M ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/M ratio in group A (n = 23)
Study: 15272100
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (SJW) extract LI 160, 300 mg twice daily for 6 weeks
Study: 11384792
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus aerobic exercise plus usual and customary care
Study: 11384792
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus usual and customary care
Study: 8491438
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (50, 100, 150, or 200 mg)
Study: 24600651
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with bovine or equine matrix
Study: 24600651
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with equine matrix
Study: 18583287
Drug: OPCAB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPCAB with cTnT <1 ng/mL
Study: 18583287
Drug: OPCAB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPCAB with cTnT >=1 ng/mL
Study: 9014651
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ca as CaCO3, consumed between meals 5 days/week for 1 year
Study: 1569347
Drug: Fleroxacin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin, 400 mg, single oral dose
Study: 1569347
Drug: Trimethoprim-sulfamethoxazole (TMP‐SMZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP‐SMZ), 160/800 mg, twice daily for 3 days
Study: 3902176
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg diltiazem
Study: 3902176
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg diltiazem
Study: 30044935
Drug: Thawed plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thawed plasma administration
Study: 26148364
Drug: Ilioinguinal‐iliohypogastric block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal‐iliohypogastric block with 10 ml 0.5% ropivacaine from each side
Study: 26148364
Drug: Transversus abdominis
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus abdominis plane block with 20 ml 0.25% ropivacaine
Study: 14669282
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) after hyper-CVAD regimen; high-dose cyclophosphamide (120 mg/kg), total body irradiation, and ASCT.
Study: 14669282
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with β2-microglobulin (β2m) level ≤ 3 mg/L at diagnosis or transplantation.
Study: 8901129
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine hydrochloride as Vendal retard film tablets
Study: 8901129
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulphate as Mundidol retard film tablets
Study: 27095446
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat load test meal (OFTT) with 0.7 g fat/kg body weight (12% SFA, 10% PUFA, 43% MUFA, 10% protein, 25% carbohydrates)